Evidence map›Paper›PMID 25580520›Full record

ArticleJournal of viral hepatitis2015

Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study.

B Hajarizadeh, B Grady, K Page, A Y Kim, B H McGovern, A L Cox, T M Rice, R Sacks-Davis, J Bruneau, M Morris and 11 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of viral hepatitis, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. 17,β-estradiol inhibits hepatitis C virus mainly by interference with the release phase of its life cycle.Liver international : official journal of the International Association for the Study of the Liver · 2017
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 11 institutions in 5 countries.

B HajarizadehThe Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
B GradyCluster Infectious Diseases, GGD Public Health Service of Amsterdam, Amsterdam, The Netherlands.
K PageDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
A Y KimHarvard Medical School, Boston, MA, USA.
B H McGovernTufts Medical School, Boston, MA, USA.
A L CoxDepartment of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
T M RiceDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
R Sacks-DavisBurnet Institute, Melbourne, Vic., Australia.
J BruneauCRCHUM, Université de Montréal, Montreal, QC, Canada.
M MorrisDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
J AminThe Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
J SchinkelAcademic Medical Center, Amsterdam, The Netherlands.
T ApplegateThe Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
L MaherThe Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
M HellardBurnet Institute, Melbourne, Vic., Australia.
A R LloydInflammation and Infection Research Centre, School of Medical Sciences, UNSW Australia, Sydney, NSW, Australia.
M PrinsCluster Infectious Diseases, GGD Public Health Service of Amsterdam, Amsterdam, The Netherlands.
R B GeskusCluster Infectious Diseases, GGD Public Health Service of Amsterdam, Amsterdam, The Netherlands.
G J DoreThe Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
J GrebelyThe Kirby Institute, UNSW Australia, Sydney, NSW, Australia.
InC3 Study Group
Australian Wool Innovation (Australia) · AUAcademic Medical Center · NLUniversity of California, San Francisco · USBurnet Institute · AUGGD Amsterdam · NLHarvard University · USJohns Hopkins University · USMonash University · AUTufts Medical Center · USUniversité de Montréal · CAUNSW Sydney · AU

Funding

UNM HSC Clinical and Translational Science CenterUL1TR001449 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI CAMPEN, MATTHEW J, PANDHI, NANCY · 2015 to 2024
$36.9M
UCSF Liver Core CenterP30DK026743 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Holger Willenbring · 1986 to 2026
$30.7M
Acute Hepatitis C Infection in Young InjectorsR01DA016017 · NIDA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI PAGE, KIMBERLY · 2002 to 2018
$14.0M
The role of NK cells during acute HCV infection and antiviral therapyU19AI066345 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LAUER, GEORG MICHAEL · 2005 to 2014
$8.5M
Scientific CoreU19AI088791 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SHAW, GEORGE M · 2010 to 2020
$8.2M
Discovery and Assessment of Genetic Determinants of HCV and HIV ControlR01DA033541 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI CHUNG, RAYMOND T, KIM, ARTHUR Y · 2011 to 2015
$3.4M
International Collaborative of prospective studies of HIV and Hepatitis in IDUR01DA031056 · NIDA · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI PAGE, KIMBERLY · 2011 to 2015
$2.2M
Canadian Institutes of Health Research MOP-103138Canadian Institutes of Health Research MOP-210232NCATS NIH HHS UL1 TR001449NIAID NIH HHS U19 AI066345NIAID NIH HHS U19 AI088791NIDA NIH HHS R01 DA016017NIDA NIH HHS R01 DA031056NIDA NIH HHS R01DA031056NIDA NIH HHS R01 DA033541NIDDK NIH HHS P30 DK026743
6 · The paper itself

Abstract

Improved understanding of natural history of hepatitis C virus (HCV) RNA levels in chronic infection provides enhanced insights into immunopathogenesis of HCV and has implications for the clinical management of chronic HCV infection. This study assessed factors associated with HCV RNA levels during early chronic infection in a population with well-defined early chronic HCV infection. Data were from an international collaboration of nine prospective cohorts studying acute HCV infection (InC(3) study). Individuals with persistent HCV and detectable HCV RNA during early chronic infection (one year [±4 months] postinfection) were included. Distribution of HCV RNA levels during early chronic infection was compared by selected host and virological factors. A total of 308 individuals were included. Median HCV RNA levels were significantly higher among males (vs females; 5.15 vs 4.74 log IU/mL; P < 0.01) and among individuals with HIV co-infection (vs no HIV; 5.89 vs 4.86; P = 0.02). In adjusted logistic regression, male sex (vs female, adjusted odds ratio [AOR]: 1.93; 95%CI: 1.01, 3.69), interferon lambda 4 (IFNL4) rs12979860 CC genotype (vs TT/CT; AOR: 2.48; 95%CI: 1.42, 4.35), HIV co-infection (vs no HIV; AOR: 3.27; 95%CI: 1.35, 7.93) and HCV genotype G2 (vs G3; AOR: 5.40; 95%CI: 1.63, 17.84) were independently associated with high HCV RNA levels (>5.6 log IU/mL = 400 000 IU/mL). In conclusion, this study demonstrated that IFNL4 rs12979860 CC genotype, male sex, HIV co-infection and HCV genotype G2 are associated with high HCV RNA levels in early chronic infection. These factors exert their role as early as one year following infection.

Indexed as

Viral LoadAdultFemaleGenotypeHepacivirusHepatitis C, ChronicHIV InfectionsHumansInterferon LambdaInterleukinsInternational CooperationMaleMiddle AgedProspective StudiesRNA, ViralSex FactorsIFNL4 protein, humanInterferon LambdaInterleukinsRNA, Viralcohort studyHCV genotypeHIVIFNL4 genotypeIL28B genotypesexviral load

Identifiers

PMID25580520
PMCPMC4496327
OpenAlexW2144076650

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.